Application research of hollow mesoporous silica nanoparticles in targeted thrombolysis for deep vein thrombosis of the lower extremities
Abstract Deep vein thrombosis (DVT) remains a critical vascular disorder with high morbidity. Traditional thrombolytic therapies face challenges such as systemic bleeding risks and low specificity. Hollow mesoporous silica nanoparticles (HMSNs) have emerged as a promising platform for targeted throm...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Discover Applied Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s42452-025-06783-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Deep vein thrombosis (DVT) remains a critical vascular disorder with high morbidity. Traditional thrombolytic therapies face challenges such as systemic bleeding risks and low specificity. Hollow mesoporous silica nanoparticles (HMSNs) have emerged as a promising platform for targeted thrombolysis due to their tunable pore structure, high drug-loading capacity (up to 40% by weight), and stimuli-responsive release. This review critically evaluates HMSN synthesis methods (sol–gel, self-assembly, silicate), their physicochemical properties, and preclinical applications in DVT models. Key advancements include pH-triggered urokinase release (85% cumulative release at pH 5.5) and ligand-mediated targeting (e.g., RGD peptides), which enhance thrombus specificity. Challenges such as long-term biocompatibility, scalability, and regulatory hurdles are discussed, alongside actionable strategies for clinical translation. Future research should prioritize optimizing ligand functionalization, conducting large-scale safety assessments, and fostering interdisciplinary collaborations. |
|---|---|
| ISSN: | 3004-9261 |